Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Jazz Pharmaceuticals plc Director's Dealing 2018

Aug 14, 2018

30751_dirs_2018-08-13_993f0e93-9cdc-4489-ae97-542a3ae7f7bd.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2018-08-09

Reporting Person: Winningham Rick E (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-08-09 Ordinary Shares M 4500 $81.76 Acquired 15594 Direct
2018-08-09 Ordinary Shares M 4500 $46.83 Acquired 20094 Direct
2018-08-09 Ordinary Shares S 9000 $176.149 Disposed 11094 Direct
2018-08-09 Ordinary Shares A 1495 $0.0 Acquired 12589 Direct
2018-08-09 Ordinary Shares S 3542 $176.3075 Disposed 9047 Direct
2018-08-09 Ordinary Shares S 3437 $176.0301 Disposed 5610 Direct
2018-08-10 Ordinary Shares S 660 $176.6108 Disposed 4950 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-08-09 Non-Qualified Stock Option (right to buy) $46.83 M 4500 Disposed 2022-08-08 Ordinary Shares (4500) Direct
2018-08-09 Non-Qualified Stock Option (right to buy) $81.76 M 4500 Disposed 2023-08-07 Ordinary Shares (4500) Direct
2018-08-09 Non-Qualified Stock Option (right to buy) $177.73 A 3735 Acquired 2028-08-08 Ordinary Shares (3735) Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.14 to $176.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

F2: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 2, 2019.

F3: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.61 to $177.1555, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

F5: This non-qualified stock option was granted on August 9, 2012 and vested over a period of one year from the grant date. The options were fully vested as of August 9, 2013.

F6: This non-qualified stock option was granted on August 8, 2013 and vested over a period of one year from September 1, 2013. The options were fully vested as of August 1, 2014.

F7: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2018.